Paragon 28 - Comprehensive Analysis Report
Summary
Paragon 28, founded in 2010, is a medical device company exclusively focused on the foot and ankle orthopedic segment. Its core mission is to continually enhance patient outcomes and experiences for those suffering from foot and ankle conditions. The company's vision drives innovation and quality, seeking to advance the science of foot and ankle surgery. The name "Paragon 28" embodies its pursuit of excellence ("Paragon") and its dedication to the 28 bones of the human foot. They specialize in developing, distributing, and selling tailored medical devices for a wide range of foot and ankle ailments, including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD), Charcot foot, and orthobiologics. Paragon 28 holds a significant position in its industry by providing a comprehensive portfolio of specialized surgical solutions and leveraging advanced technologies to improve patient care.
1. Strategic Focus & Objectives
Core Objectives
Paragon 28's main business objectives revolve around improving patient outcomes and redefining the foot and ankle specialty through innovative technologies and procedures. The company designs its products to enhance surgical results, decrease recurrence and complication rates, and ensure procedures are simpler, consistent, and reproducible for surgeons.
Specialization Areas
The company's primary expertise lies in the foot and ankle segment of the orthopedic implant market. It offers a comprehensive portfolio of surgical solutions across all major distal extremity market segments: forefoot, fracture fixation, flatfoot, ankle, Charcot, and biologics. Its unique value proposition stems from its exclusive focus, allowing for deep specialization and the development of solutions tailored to complex foot and ankle anatomy.
Target Markets
Paragon 28 primarily targets the global foot and ankle orthopedic market, with the majority of its revenue generated from the United States. Its market positioning strategy is to serve as a specialized provider offering advanced, segment-specific solutions rather than a broad orthopedic portfolio.
2. Financial Overview
Funding History
Paragon 28 was acquired by Zimmer Biomet Holdings, Inc. on April 21, 2025. The acquisition included an upfront payment of $13.00 per share in cash, totaling an equity value of approximately $1.1 billion and an enterprise value of about $1.2 billion. Paragon 28 shareholders were also eligible for a non-tradeable contingent value right (CVR) of up to $1.00 per share in cash, contingent on achieving net sales between $346 million and $361 million during Zimmer Biomet's fiscal year 2026. Prior to this acquisition, Paragon 28 was a VC-backed entity.
For the full year 2024, Paragon 28 reported net revenue in the range of $255.9 million to $256.2 million, indicating 18.2% to 18.4% reported growth over the previous fiscal year. In 2023, the company's estimated revenue was $216.7 million, an increase from $181.4 million in 2022.
3. Product Pipeline
Key Products/Services
Paragon 28 maintains a robust product pipeline, having launched over 75 systems since 2011, with additional enabling technologies under development. The company is committed to continuous product launches to address unmet needs in the foot and ankle market. Its portfolio is well-balanced, spanning sub-segments such as fracture fixation, forefoot, ankle, PCFD, Charcot foot, and orthobiologics. The company showcased new product launches at the American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference in March 2025, demonstrating its ongoing innovation. Each system typically comprises plates, screws, staples, nails, advanced joint and bone replacements, biologics, and specialized implantation instruments and disposables.
4. Technology & Innovation
Technology Stack
Paragon 28 distinguishes itself through proprietary technological platforms and a strong commitment to innovation in foot and ankle surgery.
SMART28℠: This platform integrates artificial intelligence (AI), data analytics, and 3D modeling to streamline surgical planning and execution. It offers anatomy-specific modules and patient-centric planning, providing surgeons with powerful, data-driven insights for enhanced surgical planning and improved patient outcomes.
PRESERVE™ Bone Graft System: This system features patented, procedure-specific bone wedges that are minimally manipulated and density-matched to the anatomy. The grafts are aseptically processed without gamma radiation or bleach to maintain structural integrity and osteoinductive potential. They are available in various shapes for procedures like Lapidus, MTP, Evans, Cotton, CC, and subtalar joint distraction arthrodesis, designed to support faster incorporation and higher union rates.
Gorilla® Ankle Fracture Plating System: A comprehensive system comprising 78 plates with options for fibular, hook, posterior, and pilon plates. These low-profile plates feature recessed holes for locking or non-locking screw placement, accommodating syndesmotic fixation while minimizing screw head prominence. It includes specialized plates for posterior fibula, posterior tibia, posterolateral fibula, posterolateral tibia, and posterior tibia trimalleolar fractures.
Gorilla® Ankle Fracture Pilon Plating System: This system includes 26 plates with transitional thicknesses for strength at the fracture site and tapering away to reduce soft tissue irritation. It encompasses Anterior Distal Tibia, Anterolateral Distal Tibia, and Medial Distal Tibia plating families.
APEX 3D™ Total Ankle System: This system offers a streamlined approach to total ankle arthroplasty, adaptable to surgeon preference and patient needs for various arthritic ankle conditions. Its implant designs are based on preclinical studies of arthritic tibiotalar morphology, guided by healthy ankle weight-bearing CT research, and extensive clinical investigations to mitigate complications like component loosening and implant subsidence. It incorporates features such as highly cross-linked vitamin E infused polyethylene tibial inserts.
Proprietary Developments
Paragon 28 has rapidly expanded its global intellectual property portfolio, focusing on patenting unique technologies and solutions within the foot and ankle market, such as the PRESERVE™ Bone Graft System.
5. Leadership & Management
Executive Team
Albert DaCosta: Chairman of the Board, President, and Chief Executive Officer. Mr. DaCosta is a founder of Paragon 28.
Stephen M. Deitsch: Chief Financial Officer.
Chadi Chahine: Chief Financial Officer and Executive Vice President, Supply Chain Operations.
Matthew Millard: Chief Human Resources Officer.
Matt Brinckman: Senior Vice President, Strategy and Investor Relations.
Erik E. Mickelson: Chief Accounting Officer and Controller.
Recent Leadership Changes
In January 2025, Zimmer Biomet Holdings, Inc. announced its definitive agreement to acquire Paragon 28, Inc., a transaction that was unanimously approved by the boards of directors of both companies. The acquisition officially completed on April 21, 2025, resulting in Paragon 28 operating as a subsidiary of Zimmer Biomet. Albert DaCosta remains in his roles as Chairman of the Board, President, and Chief Executive Officer of Paragon 28.
6. Talent and Growth Indicators
Hiring Trends and Workforce
As of December 31, 2023, Paragon 28 had 574 employees. The company is actively focusing on salesforce expansion to increase its market penetration and global footprint.
Company Growth Trajectory Indicators
With its acquisition by Zimmer Biomet, Paragon 28 is expected to significantly contribute to Zimmer Biomet's revenue growth, particularly within the high-growth foot and ankle segment. The global foot and ankle market is projected to grow at a 7% compound annual rate, offering a strong tailwind for Paragon 28's continued sales and workforce expansion. The company’s robust product pipeline, with over 25 active systems under development, further supports its growth trajectory.
7. Social Media Presence and Engagement
Digital Footprint
Paragon 28 maintains an active digital presence, including a YouTube channel and an Instagram account.
Brand Messaging and Positioning
The company uses these platforms to share product demonstrations, such as the SMART Bun-Yo-Matic℠, and engage with surgical professionals. Its online content showcases its latest technologies and innovations, and promotes industry events like their "Innovations in Foot and Ankle Dinner" which features insights from leading surgeons. This engagement reinforces its brand positioning as a leader in specialized foot and ankle surgical solutions.
8. Recognition and Awards
Industry Recognition
Paragon 28 consistently participates in and presents at major industry events, such as the American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference. This active presence demonstrates its recognition and standing within the orthopedic community, highlighting its commitment to advancing the field through continuous product launches and thought leadership.
9. Competitive Analysis
Major Competitors
Paragon 28 operates in a dynamic and innovation-driven competitive landscape within the foot and ankle orthopedic market. Key competitors include companies such as Treace Medical Concepts, Bioretec, and Loci Orthopaedics, among others. These entities also offer various orthopedic devices and solutions targeting foot and ankle conditions.
Competitive Positioning
Paragon 28 differentiates itself through its exclusive focus on the foot and ankle segment, allowing for unparalleled specialization and a deep understanding of specific patient and surgeon needs. This singular dedication enables the development of a comprehensive and innovative product portfolio covering all major foot and ankle categories. Furthermore, its investment in advanced technological platforms like SMART28℠, which integrates AI, data analytics, and 3D modeling, provides a distinct competitive advantage by enhancing surgical planning and outcomes. The company's commitment to research-motivated development and high-quality, cost-effective implants further strengthens its position against competitors, particularly given the ongoing need for improved solutions in ankle replacements due to historically high revision rates.
10. Market Analysis
Market Overview
The global market for implants and devices used in foot and ankle procedures is a rapidly growing segment within orthopedics, estimated at $4.9 billion and projected to reach $6.9 billion by 2028, with an annual growth rate of approximately 7%. The United States represents the largest market for these procedures and is Paragon 28's primary revenue source.
Growth Potential, Trends, and Opportunities
Market growth is fueled by an aging population, increasingly active lifestyles, and continuous technological advancements, including the integration of data analytics and AI into surgical processes. The inherent complexity of foot and ankle anatomy, coupled with a historical lack of dedicated solutions from larger orthopedic players, has created a significant demand for specialized, high-quality solutions that improve clinical outcomes. This market dynamic presents substantial opportunities for specialized companies like Paragon 28 to continue their growth trajectory.
11. Strategic Partnerships
Partner Organization
Zimmer Biomet Holdings, Inc.
Nature of Partnership
The most significant strategic development for Paragon 28 is its acquisition by Zimmer Biomet. This alliance represents a full integration of Paragon 28 into Zimmer Biomet's operations.
Strategic Benefits
This strategic partnership significantly strengthens Zimmer Biomet's foot and ankle offerings by integrating Paragon 28's leading technology platform and specialized product suite. It also bolsters Zimmer Biomet's existing fracture & trauma and joint replacement portfolios. The combined entity is expected to drive greater market adoption and accelerate both U.S. and international growth through leveraging Zimmer Biomet's extensive global footprint and existing infrastructure. This collaboration substantially expands Paragon 28's market reach, distribution capabilities, and innovation potential.
12. Operational Insights
Paragon 28’s operational success is built on its exclusive dedication to the foot and ankle market. This singular focus enables the company to gain a deep understanding of specific patient and surgeon needs, leading to the development of a comprehensive and innovative product portfolio that directly addresses the complexities of foot and ankle anatomy and conditions. Its emphasis on research-motivated development, creative innovation, and high-quality, cost-effective implants provides a strong competitive advantage. The integration of advanced technologies, such as AI, data analytics, and 3D modeling into surgical planning, further enhances its operational efficiency and competitive edge by improving precision and patient outcomes.
13. Future Outlook
Strategic Roadmap
Paragon 28's strategic roadmap is focused on sustained expansion and innovation within the foot and ankle orthopedic market. Key planned initiatives and growth strategies include:
Robust Pipeline Development: With over 25 active systems in its pipeline, the company has a strong foundation for future revenue growth and addressing evolving market needs.
Salesforce Expansion: Continued investment in expanding its salesforce will drive increased market penetration and global footprint.
Surgeon Training: Ongoing education and training programs for surgeons on Paragon 28's solutions are crucial for broader adoption and improved clinical outcomes.
International Expansion: International markets currently represent approximately 15% of sales, indicating significant untapped opportunities for further global growth.
Technological Advancements: Leveraging new technologies driven by meaningful research, data analytics, and AI, such as the SMART28℠ platform, is expected to lead to higher procedural success rates and increased procedure volume.
Expansion Opportunities and Challenges
The acquisition by Zimmer Biomet is expected to immediately
